Quantity Does Not Equal Quality in Evaluating a Scientist’s Importance as a Key Opinion Leader
|
|
Lnx Pharma White Paper #6 Research Report: Social Network Analysis Yields Finding that 50% of all Key Scientific Leaders Are “Low Publishers” in Scientific Journals Quantity Does Not Equal Quality in Evaluating a Scientist’s Real Importance as a Key Opinion Leader |
Date published: Feb 2010
This study questions current methodology used extensively in pharmaceutical and biotech industries to find Key Opinion Leaders (KOLs) and influential thought leaders.
Key Takeaway: Finding key opinion leaders and effectively engaging thought leadership creates competitive advantage. The top–down approach – to analyze an entire medical research area using social network analysis – far surpasses the current bottom–up method that relies on standard publicity/publishing metrics.
Who Should Read This: Medical and Biomedical executives seeking new thinking from 3rd party thought leadership and advocates in scientific advisory board and medical affairs KOL capacities.
Specifically:
• KOL Relationship Management
• Opinion Leader Relations
• Medical and Scientific Affairs
• Scientific Advisory Board Managers
• Senior Marketing Managers
• Medical Science Liaisons
• Medical Research Executives
• Advocacy Development
• Market Research
• Brand and Product Management
Why This is Important: Pharmaceutical and biotechnology companies of all sizes are affected by ongoing changes in legislation surrounding the appropriate use of industry thought leadership in development and marketing of medical products. Companies that evolve their advocacy strategies using undiscovered relationships and powerful people often find their go-to-market strategies positively impacted.
Free Download. Please provide your name and email to be added to future notices about our research. We respect your privacy.
No thanks, just let me see the paper.